The European Patent Office (EPO) granted the patent for Dental pulp regeneration technology developed by Chilean researchers of the Universidad de los Andes , led by Dr. Claudia Brizuela, together with Dr. Maroun Khoury, scientific director of Cells for Cells and researcher of the Faculty of Medicine (EP3568141).
This unique methodology, is based on a "biofiller" that consists of stem cells encapsulated in blood-derived matrix which allows the revitalization of the dental pulp, allowing for continued development of the root and surrounding tissue. A direct effect would be the reinstatement of the immune defense against new infections. For further information see the IDTechEx report on Tissue Engineering 2018-2028: Technologies, Markets, Forecasts.
The procedure is also intent to maintain the structural integrity of the tooth, improving its biomechanical behaviour.
Cell therapy applications are advancing at a swift pace and with results recognized by the world's medical community. The multidisciplinary team from the University of los Andes and its spinoff, Cells for Cells in Chile, decided to use the concept of tissue engineering and cell therapy to restore the root canals to a healthy state, allowing for continued development of the root and surrounding tissue.
They first isolated a specific type of stem cells called mesenchymal stem cells or MSC from newborn baby umbilical cords. These cords after being considered for a long time as medical waste they are now being used as the main source for harvesting stem cells. Applying a simple but effective upcycling procedure, the Chilean team was able to isolate and expand sufficient cells that where then, encapsulated in a natural biomaterial obtained from a universal donor.
This biofiller containing the stem cells was branded as CELLISTEM®ER. "This was a blunt step forward, as we transferred the gained know-how from regenerative medicine to regenerative endodontics. It is a warranted procedure, taking into consideration all the previous clinical experience gained by our team, where we applied the cellular product to patients with heart and joint diseases," quote Dr. Khoury, co-inventor of the patent.
According to Dr. Brizuela, the implantation of CELLISTEM®ER inside the compromised tooth cavity allowed the restoration of the lost sensitive functions and increased the blood flow. These relevant outcomes are currently not achievable with the available treatments including: conventional endodontics (gutta-percha filling), tooth extractions and dental implants. In addition, a repair of the alveolar bone was observed in the event of an apical lesion.
This technology was selected for a presentation at the TechConnect World Business Program & Expo. The aim is to connect this new dental technology with industry explorers, investment partners and federal funding opportunities.
Source and top image: Cells for Cells